A pilot study of total-body PET using FDA-approved radiotracers

Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!

a study on Prostate Cancer Breast Cancer Neuroendocrine Tumor

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Sacramento, California
Dates
study started
study ends around
Principal Investigator
by Lorenzo Nardo, MD

Description

Summary

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

Official Title

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Keywords

Prostate Cancer, Breast Cancer, Neuroendocrine Tumors, Prostatic Neoplasms, Breast Neoplasms, Total-body PET imaging, Total-body PET scan

Eligibility

For people ages 18 years and up

18F-PSMA (n=3) and 68Ga-PSMA (n=3)

Inclusion criteria:

  • Persons >18 yo with suspected prostate cancer metastasis

  • Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date.

    68Ga DOTATATE (n=3) or 64Cu-DOTATATE (n=3)

Inclusion Criteria:

  • Persons > 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs)
  • Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months from the research scan date.

Exclusion Criteria:

• Recent administration of long-acting somatostatin analogs

Exclusion Criteria for all participants:

  • Adults unable to consent
  • Pregnant/lactating persons
  • Prisoners
  • Unable to lie supine for up to 90 minutes at different timepoints in the PET scanner
  • Uncontrolled claustrophobia
  • Any significant medical condition that in the opinion of the investigator would prevent the participant from participating and/or adhering to study related procedures or interfere with participant safety

Location

  • UC Davis EXPLORER Molecular Imaging Center
    Sacramento California 95816 United States

Lead Scientist at UC Davis

  • Lorenzo Nardo, MD
    Professor, MED: Radiology, School of Medicine. Authored (or co-authored) 154 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Davis
Links
Sign up for this study
ID
NCT05160480
Study Type
Observational
Participants
Expecting 9 study participants
Last Updated